Physician

Stephen John Vara, M.D.

According to 2025 Medicare claims, Stephen Vara, M.D. (NPI: 1356545818) practices hematology/oncology in the Punta Gorda, FL market, with the plurality of this provider's patient population coming from Charlotte, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33980-2012.

Vara's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,655 traditional Medicare patients, billed 401,773 HCPCS/CPT codes, and received $5,570,859 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,173 prescription claims across 437 beneficiaries totaling $4,230,055 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 36 claims. Open Payments data shows 35 records totaling $756. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $143,388 to $5,570,859. Similarly, Part D prescription costs have moved sharply higher in recent years, from $816,482 to $4,230,055. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $7,154 to $78,014.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	345	1,670	$143,388
2016	415	2,020	$172,003
2017	451	2,101	$179,443
2018	467	2,184	$181,741
2019	328	902	$68,304
2020	651	5,903	$210,109
2021	827	39,895	$709,300
2022	1,310	275,956	$3,369,776
2023	1,613	326,871	$4,723,099
2024	1,655	401,773	$5,570,859

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	131	799	$816,482
2016	149	1,030	$1,096,241
2017	177	1,342	$1,779,540
2018	180	1,177	$2,024,975
2019	129	639	$1,272,019
2020	15	27	$906
2021	49	98	$110,898
2022	221	1,082	$1,739,619
2023	333	1,572	$2,616,331
2024	437	2,173	$4,230,055

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	102	$23,231
2016	N/R	199	$20,705
2017	N/R	71	$9,845
2018	N/R	59	$12,205
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	30	30	$77,873
2023	N/R	36	$8,751
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	525	1,154	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	422	556	$65
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	558	941	$13
36415	Insertion of needle into vein for collection of blood sample	1,114	2,841	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,039	2,867	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	52	1,211	$724,707
Pomalyst	Pomalidomide	19	532	$424,675
Brukinsa	Zanubrutinib	30	900	$356,908
Verzenio	Abemaciclib	24	672	$354,755
Jakafi	Ruxolitinib Phosphate	16	480	$265,947

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	35	$756	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Stephen John Vara, M.D.?

Tedicare shows public-source Medicare data for Stephen John Vara, M.D. (NPI 1356545818), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Stephen John Vara, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Stephen John Vara, M.D.?

Stephen John Vara, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Stephen John Vara, M.D. have Open Payments data?

Stephen John Vara, M.D. has 35 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.